Skip to main content
Toxicology Reports logoLink to Toxicology Reports
. 2022 May 2;9:1023. doi: 10.1016/j.toxrep.2022.04.009

Retraction notice to “Use of ivermectin in the treatment of Covid-19: A pilot trial” [Toxicol. Rep. 8 (2021) 505–510]

Henrique Pott-Junior a,, Mônica Maria Bastos Paoliello b, Alice de Queiroz Constantino Miguel c, Anderson Ferreira da Cunha d, Caio Cesar de Melo Freire d, Fábio Fernandes Neves a, Lucimar Retto da Silva de Avó a, Meliza Goi Roscani a, Sigrid De Sousa dos Santos a, Silvana Gama Florêncio Chach´ a
PMCID: PMC9060540  PMID: 35528725

This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal).

The article has been retracted at the request of the Founding Editor, Prof. Lawrence H. Lash, on the basis that there is clear evidence that the findings are unreliable: https://publicationethics.org/files/retraction-guidelines-cope.pdf.

Additional external review of this published paper raised several concerns. While a properly conducted clinical trial is certainly welcome, the experimental design of this study lacks sufficient details for some of the methods and approaches, uses inappropriate or inadequate statistical analysis, and presents unclear data interpretation.

The conclusions and statements of the authors cannot be readily supported by the information presented in the paper.

Additionally, no reference is made to the well-known controversies that surrounded the recommended use of ivermectin to treat infections with COVID-19. https://www.nature.com/articles/d41586-020-01695-w; https://www.the-scientist.com/news-opinion/surgisphere-sows-confusion-about-another-unproven-covid19-drug-67635 The omission of any discussion of these controversies in the present paper makes the paper misleading and unacceptable.


Articles from Toxicology Reports are provided here courtesy of Elsevier

RESOURCES